NATURAL VITAMIN E FORMS AS ANTI-INFLAMMATORY DRUGS
天然维生素 E 形式作为抗炎药物
基本信息
- 批准号:7062439
- 负责人:
- 金额:$ 33.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-15 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:alternative medicineantiinflammatory agentsaspirincombination chemotherapydrug interactionsdrug screening /evaluationeicosanoid metabolismeicosanoidsinflammationlaboratory ratnonhuman therapy evaluationnutrition related tagoxidoreductase inhibitorprostaglandin endoperoxide synthasetissue /cell culturetocopherolsvitamin therapy
项目摘要
DESCRIPTION (provided by applicant): Chronic inflammation constitutes one of the major etiologies of degenerative diseases including cancer, and cardiovascular and neurodegenerative diseases; chronic inflammation also contributes to rheumatoid arthritis, asthma and hepatitis. These diseases are among the leading causes of death and disability in the world. During inflammation, several pro-inflammatory mediators including prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), as well as cytokines, such as TNF-alpha, play central roles in regulating inflammatory response and inflammation-mediated damage. Vitamin E comprises eight structurally related molecules, alpha-,beta-, gamma-, delta-tocopherol, and alpha-,beta-, gamma-, delta -tocotrienol. Among them, only alpha -tocopherol (alphaT) has been extensively studied. Recent studies indicate that other forms of vitamin E have unique properties, which are not shared by alphaT, but are important to human disease prevention and therapy. Gamma-Tocopherol (gammaT) and its metabolite, but not aT, exhibit anti-inflammatory effects by inhibiting cyclooxygenase (COX)- catalyzed formation of PGE2. In a rat inflammation model, gammaT inhibits not only PGE2, but also LTB4, and TNF-alpha. These results suggest that gammaT may be superior to some commonly used non-steroid anti-inflammatory drugs (NSAIDs), such as COX inhibitors, most of which only inhibit the COX-mediated pathway. Preliminary studies also indicate that delta- tocopherol and gamma-tocotrienol, compared with gammaT, are even stronger inhibitors of the COX-catalyzed formation of PGE2. These observations led to the current hypothesis that certain forms of vitamin E and their combinations have unique pharmaceutical utility as anti-inflammatory drugs, or as supplements that complement and improve current treatments for inflammatory diseases. This hypothesis will be tested by pursuit of the following Specific Aims in cell culture and animal experiments: 1. Investigate in vitro anti-inflammatory properties of individual vitamin E forms and their combinations; 2. Investigate and compare in vivo anti-inflammatory activities of individual vitamin E forms and their combinations; and 3. Investigate the potentially improved effects of combining certain forms of vitamin E and NSAIDs, such as aspirin, in a rat inflammation model. Our studies may lead to the discovery of novel and better therapy for treating and preventing inflammatory diseases, and provide the scientific rationale, the experimental evidence and the biochemical basis for future human studies.
描述(申请人提供):慢性炎症是包括癌症、心血管和神经退行性疾病在内的退行性疾病的主要病因之一;慢性炎症还会导致类风湿性关节炎、哮喘和肝炎。这些疾病是世界上死亡和残疾的主要原因之一。在炎症过程中,前列腺素 E2 (PGE2) 和白三烯 B4 (LTB4) 等多种促炎介质以及 TNF-α 等细胞因子在调节炎症反应和炎症介导的损伤中发挥着核心作用。维生素 E 包含八种结构相关的分子:α-、β-、γ-、δ-生育酚和 α-、β-、γ-、δ-生育三烯酚。其中,只有α-生育酚(alphaT)得到了广泛的研究。最近的研究表明,其他形式的维生素 E 具有 alphaT 不具备的独特性质,但对人类疾病的预防和治疗很重要。 γ-生育酚 (gammaT) 及其代谢物(但不是 aT)通过抑制环氧合酶 (COX) 催化的 PGE2 形成而表现出抗炎作用。在大鼠炎症模型中,gammaT 不仅抑制 PGE2,还抑制 LTB4 和 TNF-α。这些结果表明,gammaT 可能优于一些常用的非类固醇抗炎药 (NSAID),例如 COX 抑制剂,其中大多数仅抑制 COX 介导的途径。初步研究还表明,与 gammaT 相比,δ-生育酚和 γ-生育三烯酚是 COX 催化的 PGE2 形成的更强抑制剂。这些观察结果得出了目前的假设,即某些形式的维生素 E 及其组合具有独特的药物用途,可作为抗炎药,或作为补充和改善当前炎症性疾病治疗的补充剂。这一假设将通过在细胞培养和动物实验中追求以下具体目标来检验: 1. 研究单个维生素 E 形式及其组合的体外抗炎特性; 2. 研究并比较维生素E单独形式及其组合的体内抗炎活性; 3. 研究在大鼠炎症模型中联合使用某些形式的维生素 E 和 NSAID(例如阿司匹林)的潜在改善效果。我们的研究可能会发现治疗和预防炎症性疾病的新的、更好的疗法,并为未来的人类研究提供科学原理、实验证据和生化基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qing Jiang其他文献
Qing Jiang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qing Jiang', 18)}}的其他基金
Anti-inflammatory mechanisms, pharmacokinetics of novel metabolites of vitamin E
维生素E新型代谢物的抗炎机制、药代动力学
- 批准号:
8196666 - 财政年份:2011
- 资助金额:
$ 33.44万 - 项目类别:
The Role of a Novel Vitamin E Metabolite in Colon Cancer Prevention and Therapy
新型维生素 E 代谢物在结肠癌预防和治疗中的作用
- 批准号:
8230605 - 财政年份:2011
- 资助金额:
$ 33.44万 - 项目类别:
Anti-inflammatory mechanisms, pharmacokinetics of novel metabolites of vitamin E
维生素E新型代谢物的抗炎机制、药代动力学
- 批准号:
8326747 - 财政年份:2011
- 资助金额:
$ 33.44万 - 项目类别:
The Role of a Novel Vitamin E Metabolite in Colon Cancer Prevention and Therapy
新型维生素 E 代谢物在结肠癌预防和治疗中的作用
- 批准号:
8099210 - 财政年份:2011
- 资助金额:
$ 33.44万 - 项目类别:
Gamma-tocopherol as an effective anticancer agent for colon cancer
γ-生育酚作为结肠癌的有效抗癌剂
- 批准号:
7752828 - 财政年份:2009
- 资助金额:
$ 33.44万 - 项目类别:
Gamma-tocopherol as an effective anticancer agent for colon cancer
γ-生育酚作为结肠癌的有效抗癌剂
- 批准号:
7580180 - 财政年份:2009
- 资助金额:
$ 33.44万 - 项目类别:
NATURAL VITAMIN E FORMS AS ANTI-INFLAMMATORY DRUGS
天然维生素 E 形式作为抗炎药物
- 批准号:
6801784 - 财政年份:2003
- 资助金额:
$ 33.44万 - 项目类别:
NATURAL VITAMIN E FORMS AS ANTI-INFLAMMATORY DRUGS
天然维生素 E 形式作为抗炎药物
- 批准号:
7076096 - 财政年份:2003
- 资助金额:
$ 33.44万 - 项目类别:
NATURAL VITAMIN E FORMS AS ANTI-INFLAMMATORY DRUGS
天然维生素 E 形式作为抗炎药物
- 批准号:
7010222 - 财政年份:2003
- 资助金额:
$ 33.44万 - 项目类别:
相似国自然基金
靶向HDAC3/SIAH2蛋白复合物的HDAC3降解剂的作用机制、结构改造及非酶活功能介导的抗炎活性研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
卡萨烷选择性调控糖皮质激素受体GR功能的抗炎作用机制与新颖调控剂的设计与发现
- 批准号:82273824
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
ZAP-70选择性共价抑制剂及降解剂的设计合成和抗炎活性研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于片段的P2Y14受体拮抗剂的设计、合成和抗炎活性研究
- 批准号:
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
两种民族药用植物中黄酮类ILCreg诱导剂的发现及其抗炎性肠病机制探究
- 批准号:81960777
- 批准年份:2019
- 资助金额:34 万元
- 项目类别:地区科学基金项目
相似海外基金
Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
- 批准号:
10644089 - 财政年份:2023
- 资助金额:
$ 33.44万 - 项目类别:
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
多功能抗血栓治疗冠状动脉微血管阻塞
- 批准号:
10696319 - 财政年份:2023
- 资助金额:
$ 33.44万 - 项目类别:
ZZ-3K3A-301: A multicenter, randomized, placebo-controlled, double-blinded, Phase 3 study to evaluate the efficacy and safety of 3K3A-APC (RHAPSODY-2)
ZZ-3K3A-301:一项多中心、随机、安慰剂对照、双盲、3 期研究,旨在评估 3K3A-APC (RHAPSODY-2) 的有效性和安全性
- 批准号:
10305528 - 财政年份:2022
- 资助金额:
$ 33.44万 - 项目类别:
Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
- 批准号:
10491205 - 财政年份:2021
- 资助金额:
$ 33.44万 - 项目类别:
Developing a new drug for treating myocardial ischemia/reperfusion injury
开发治疗心肌缺血/再灌注损伤的新药
- 批准号:
10325868 - 财政年份:2021
- 资助金额:
$ 33.44万 - 项目类别: